The Implications of Blood Transfusions for Patients With Non–ST-Segment Elevation Acute Coronary Syndromes
Results From the CRUSADE National Quality Improvement Initiative
Xin Yang, MD, MRCP*,
Karen P. Alexander, MD, FACC*,
Anita Y. Chen, MS*,
Matthew T. Roe, MD, MHS, FACC*,
Ralph G. Brindis, MD, MPH, FACC ,
Sunil V. Rao, MD*,
W. Brian Gibler, MD ,
E. Magnus Ohman, MD, FACC ,
Eric D. Peterson, MD, MPH, FACC*,* for the CRUSADE Investigators
* Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina
Kaiser-Permanente San Francisco Medical Center, San Francisco, California
University of Cincinnati School of Medicine, Cincinnati, Ohio
Division of Cardiology, University of North Carolina, Chapel Hill, North Carolina
View larger version (24K):
[in a new window]
|
Figure 1 Transfusion by age group for non-coronary artery bypass grafting (CABG) and overall population. Use of transfusion by age group among the overall population (hatched bars) and the subset excluding patients who underwent coronary artery bypass grafting during hospitalization (solid bars).
|
|
View larger version (24K):
[in a new window]
|
Figure 2 Transfusion practices across hospitals. Distribution of hospitals according to the percent of their overall (hatched bars) and non-coronary artery bypass grafting (CABG) population (solid bars) that underwent transfusion.
|
|
View larger version (22K):
[in a new window]
|
Figure 3 Age and transfusion as a function of the number of antithrombin and antiplatelet agents used. Acute (<24 h) agents considered include: 1) aspirin or clopidogrel, 2) unfractionated heparin, 3) low molecular weight heparin, and 4) glycoprotein IIb/IIIa inhibitors. Rate of transfusion displayed by patient age and number of agents delivered during hospital stay.
|
|
|
